AIP Form 4: CEO Janac executes 10b5-1 sales totaling 105,755 shares
Rhea-AI Filing Summary
Arteris, Inc. director, president and CEO Janac K. Charles reported sales under a pre-established 10b5-1 plan. On 10/06/2025 the reporting person sold 5,755 shares at a listed price of $14 and sold an additional 100,000 shares at a weighted average price of $13.1045 (individual trades ranged from $12.50 to $13.85). After these transactions, direct beneficial ownership is reported as 161,759 shares and indirect ownership through entities is 9,739,071 shares. The filing notes the sales were executed pursuant to a trading plan adopted on 03/05/2025.
Positive
- Sales executed under a 10b5-1 trading plan, which provides structured timing and an affirmative defense when adopted in good faith
- Reporting person retains substantial indirect ownership of 9,739,071 shares after the transactions, indicating continued alignment with shareholders
Negative
- Insider sold 100,000 shares (plus 5,755 shares) on 10/06/2025, which could reduce insider-held liquidity buffer
- Weighted average sale price for the larger tranche was $13.1045, below one reported sale at $14, indicating sales executed across a price range
Insights
Insider sales occurred under a documented 10b5-1 plan; ownership remains concentrated.
The reporting person holds multiple roles as President & CEO, director and a 10% owner, and retains significant indirect ownership totaling 9,739,071 shares after the reported sales. The filing explicitly states the sales were made under a 10b5-1 plan adopted on 03/05/2025, which provides an affirmative defense against insider trading claims when properly adopted.
Key dependencies include the continued existence of the plan and any future scheduled transactions; investors may note the filing date 10/08/2025 as the formal report date for these executed trades.
Executed sales were modest relative to total beneficial holdings; proceeds reflect routine plan-driven liquidity.
The reporting person sold a total of 105,755 shares on 10/06/2025 at prices ranging from $12.50 to $14, with a weighted average of $13.1045 for the larger tranche. Compared with combined reported ownership (~9.9M shares), the trades represent a small percentage of aggregate holdings.
Primary risks to monitor are any additional scheduled dispositions under the 10b5-1 plan and whether future filings show materially larger sales; those would be the near-term items to watch.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 5,755 | $14.00 | $81K |
| Sale | Common Stock | 100,000 | $13.1045 | $1.31M |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- Transaction made pursuant to a 10b5-1 trading plan that was adopted by the Reporting Person on March 5, 2025. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $12.50 to $13.85 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The Reporting Person is the manager of Bayview Legacy, LLC and as such is deemed to have voting and dispositive power of the shares beneficially owned by Bayview Legacy, LLC. The shares are held by Charles and Lydia Janac Trust, for which the Reporting Person serves as trustee.
